Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival

Combination therapies against multiple targets are currently being developed to prevent resistance to a single chemotherapeutic agent and to extirpate pre-existing resistance in heterogeneous cancer cells in tumors due to selective pressure from the single agent. Gemcitabine (GEM), a chemotherapeuti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Drug Des Devel Ther
Main Authors: Allison Logan, Stephanie, Brissenden, Amanda J, Szewczuk, Myron R, Neufeld, Ronald J
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2017
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546735/
https://ncbi.nlm.nih.gov/pubmed/28814832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S137934
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares